BioArctic stock: fair value
BIOA-B.STThe fair value of BioArctic under our model is $50.17, the price is 37% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 13 Nov 2026
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $35.84 and expensive above $83.62 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $97.75 (cash-flow model) and $2.59 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $41.55, at 6.3% it would be $63.02.
Where the number comes from
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Ten-year cash-flow model from smoothed free cash flow and its past growth until it reaches 2.2%. Discounted at 7.3% (government bond yield 2.2% plus beta 1.21 times a risk premium of 4.2%); no analyst estimates were available.
Calculate with your own assumptionsThe calculation step by step
With these figures the cash flow model arrives at $97.75 per share: free cash flow for the next ten years, each year discounted to today at 7.3%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 7.3%) |
|---|---|---|---|---|
| 2026 | $205.93M | extrapolated at 45.0% | 0.9318 | $191.89M |
| 2027 | $272.15M | extrapolated at 32.2% | 0.8683 | $236.31M |
| 2028 | $335.19M | extrapolated at 23.2% | 0.8091 | $271.21M |
| 2029 | $391.74M | extrapolated at 16.9% | 0.7540 | $295.35M |
| 2030 | $440.56M | extrapolated at 12.5% | 0.7026 | $309.52M |
| 2031 | $481.87M | extrapolated at 9.4% | 0.6547 | $315.46M |
| 2032 | $516.65M | extrapolated at 7.2% | 0.6100 | $315.18M |
| 2033 | $546.14M | extrapolated at 5.7% | 0.5684 | $310.45M |
| 2034 | $571.53M | extrapolated at 4.7% | 0.5297 | $302.74M |
| 2035 | $593.86M | extrapolated at 3.9% | 0.4936 | $293.12M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $2.84B |
| Terminal value: cash flow 2035 × (1 + 2.2%) / (7.3% − 2.2%) | $11.82B |
| Present value of terminal value (× 0.4936) | $5.83B |
| Equity value (sum plus present value of terminal value) | $8.67B |
| Shares (diluted) | 88.72M |
| Value per share (equity value divided by shares) | $97.75 |
| Earnings per share, last twelve months | $0.12 |
| × 21.7 (industry P/E) | $2.59 |
| Fair value (average of both parts) | $50.17 |
The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.